Get the Stockscreener App
1.13
8.87%
-0.11
After Hours:
1.14
0.01
+0.88%
Lunai Bioworks Inc stock is traded at $1.13, with a volume of 461.97K.
It is down -8.87% in the last 24 hours and up +0.00% over the past month.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
See More
Previous Close:
$1.24
Open:
$1.22
24h Volume:
461.97K
Relative Volume:
16.21
Market Cap:
$28.74M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-12.40%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.1208
$1.2438
1-Week Range:
$1.1208
$1.39
52-Week Range:
$1.1208
$1.39
Lunai Bioworks Inc Stock (LNAI) Company Profile
Name
Lunai Bioworks Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
1.13 | 28.74M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lunai Bioworks Inc Stock (LNAI) Latest News
Lunai Bioworks reports 35% improvement in Alzheimer’s diagnostics - Investing.com
Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline - PharmiWeb.com
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - Online Athens
Seven new option listings and two option delistings on October 1st - TipRanks
LNAI Stock Price and Chart — NASDAQ:LNAI - TradingView
Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on - PharmiWeb.com
AI Drug Discovery Pioneer Lunai Bioworks Emerges with New Identity and Streamlined 23.2M Share Structure - Stock Titan
Analyzing Climb Bio (NASDAQ:CLYM) & Lunai Bioworks (NASDAQ:RENB) - Defense World
Renovaro Biosciences Announces Reverse Stock Split - TipRanks
Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split - PharmiWeb.com
Lunai Bioworks to effect 10:1 reverse stock split - MSN
Lunai Bioworks stock plunges after announcing 10:1 reverse split By Investing.com - Investing.com UK
$1.85M NIH Grant Powers Lunai Bioworks' AI Platform to Combat Alcohol Disorder Affecting 19M Americans - Stock Titan
Top 3 Health Care Stocks You'll Regret Missing In Q3 - Sahm
Lunai Bioworks launches transformer-base platform to secure GenAI - Yahoo Finance
Lunai Bioworks (RENB) Restructures European Operations for Strat - GuruFocus
AI Drug Discovery Firm Lunai Bioworks Restructures European Business, Maintains Growth Strategy - Stock Titan
Renovaro Biosciences Faces Subsidiary Bankruptcy Impact - TipRanks
Lunai Bioworks Inc. Retains American Defense International - PharmiWeb.com
User - FinancialContent
Renovaro Inc. changes corporate name to Lunai Bioworks Inc., maintains Nasdaq symbol - Investing.com
Merger Crisis: Renovaro Threatens Legal Action After Predictive Oncology Backs Out - Stock Titan
RENBRenovaro Latest Stock News & Market Updates - Stock Titan
Enochian Biosciences Is A House Of CardsThe Pipeline Is Entirely Pre-Clinical And Management Has A Questionable History (NASDAQ:RENB) - Seeking Alpha
Lunai Bioworks Inc Stock (LNAI) Financials Data
There is no financial data for Lunai Bioworks Inc (LNAI). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):